In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lorus Virulizin pancreatic cancer data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lorus Therapeutics believes its immunotherapy Virulizin could benefit a subgroup of pancreatic cancer patients with ECOG performance status of 0 or 1, the firm says Oct. 18. The Toronto biotech found, however, that its Phase III trial did not show statistical significance for median overall survival in chemo-naïve patients receiving Virulizin plus gemcitabine compared to placebo plus gemcitabine. "For the efficacy evaluable population, the study showed that the addition of Virulizin to gemcitabine resulted in a median [OS] of 6.8 months and a one-year survival rate of 27.2%, compared to 6.0 months and 16.8% for placebo plus gemcitabine," Lorus said. In ECOG PS 0/1 patients, "the result approached statistical significance with a p-value of 0.063"...

You may also be interested in...

BMS's Rebloyzl Data Supports Adding Less Severe Patients To Label

Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.

Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm

Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.

Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far

Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts